LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SCLX
Scilex Holding Company
There isn't enough reported data to score SCLX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SCLX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
SCLX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SCLX PE Valuation
SCLX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.5x next year's earnings.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SCLX on the outlook, with more favorable profitability expectations.
SCLX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect SCLX to return to profit, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SCLX in the latest year-over-year earnings comparison.
SCLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | — |
| Q3 2025 | -$31.88 | -$3.18 |
SCLX lost $31.88 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SCLX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SCLX on profitability, with a higher operating margin.
SCLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.6M | -23% |
| Q1 2026 | $8.6M | +72% |
| Q4 2025 | $4.8M | -68% |
| Q3 2025 | $10.6M | -27% |
| Q2 2025 | $9.9M | -40% |
| Q1 2025 | $5M | -54% |
| Q4 2024 | $14.9M | +11% |
| Q3 2024 | $14.4M | +43% |
SCLX's revenue has slid since its 2024 peak: $8M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -385% | -178 points |
| Q1 2026 | -373% | +184 points |
| Q4 2025 | -2318% | -2127 points |
| Q3 2025 | -1766% | -1628 points |
| Q2 2025 | -207% | -112 points |
| Q1 2025 | -558% | -379 points |
| Q4 2024 | -190% | -54 points |
| Q3 2024 | -138% | +246 points |
SCLX's operating margin was −385% last quarter, down 178 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
SCLX has the stronger cash trend. Its trailing FCF is up 271% versus its history, compared with LLY at up 259%.
SCLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | -118% |
| Q3 2025 | $8.2M | +61% |
| Q1 2025 | $6M | -36% |
| Q4 2024 | $2.5M | +$7.9M |
| Q3 2024 | $5.1M | -13% |
| Q1 2024 | $9.4M | +$17.1M |
| Q3 2023 | $5.9M | +$6.2M |
| Q1 2023 | -$7.7M | -$6.9M |
SCLX usually generates cash, though not every quarter: the latest was −$1M, but it generated $20M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SCLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -115K shares |
| 1 year | -24% | -116K shares |
SCLX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SCLX Net Leverage
SCLX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SCLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 0.8 | Oversold |
SCLX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SCLX PE vs Healthcare Sector
| Metric | SCLX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCLX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SCLX on trend strength, trading above more of its moving averages.
SCLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.77 | 44% below |
| 20 week MA | $5.09 | 69% below |
| 50 week MA | $7.45 | 79% below |
| 100 week MA | $10.2 | 85% below |
| 200 week MA | $62.2 | 97% below |
SCLX is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SCLX on returns for 2026, with the stronger performance.
SCLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $344.8 | $351.4 | +1.9% |
| 2022 | $351.4 | $117.3 | -67% |
| 2023 | $117.3 | $71.4 | -39% |
| 2024 | $71.4 | $13.7 | -81% |
| 2025 | $13.7 | $14.1 | +3.3% |
| 2026 YTD | $14.1 | $1.56 | -89% |
SCLX has finished lower in three of the last five years. It's down 89% so far in 2026.